Featured Research

from universities, journals, and other organizations

Epidural Steroid Injections Limited In Treating Back Pain, New Guideline Finds

Date:
March 6, 2007
Source:
American Academy of Neurology
Summary:
A guideline developed by the American Academy of Neurology finds epidural steroid injections play a limited role in providing short-term pain relief for lower back pain that radiates down a leg, and do not provide long-term pain relief. The guideline is published in the March 6, 2007, issue of Neurology, the scientific journal of the American Academy of Neurology.

A guideline developed by the American Academy of Neurology finds epidural steroid injections play a limited role in providing short-term pain relief for lower back pain that radiates down a leg, and do not provide long-term pain relief. The guideline is published in the March 6, 2007, issue of Neurology®, the scientific journal of the American Academy of Neurology.

To develop the guideline, the authors analyzed scientific studies on the topic.

According to the guideline, epidural steroid injections may provide some short-term pain relief between two and six weeks after injection, but the average amount of relief is small.

"While some pain relief is a positive result in and of itself, the extent of leg and back pain relief from epidural steroid injections, on the average, fell short of the values typically viewed as clinically meaningful," said lead author Carmel Armon, MD, MHS, Chief, Division of Neurology, with Baystate Medical Center in Springfield, Massachusetts, and Professor of Neurology at Tufts University School of Medicine in Boston, Massachusetts. Armon is also a Fellow member of the American Academy of Neurology.

The guideline also found epidural steroid injections usually did not help patients "buy time" to avoid surgery, or provide long-term pain relief beyond three months. Their routine use for these purposes is not recommended.

"The use of epidural steroid injections to treat chronic back pain is increasing over time despite limited quality data," said Armon. "Recent figures show 1999 Medicare Part B claims for lumbar epidural steroid injections were $49.9 million, for 40.4 million covered individuals."

In addition, the authors also found insufficient evidence to use epidural steroid injections to treat radicular cervical pain, or neck pain.

Armon says the review was limited by the small number of high-quality scientific studies on epidural steroid injections, and further well-designed studies are needed to determine their effectiveness.


Story Source:

The above story is based on materials provided by American Academy of Neurology. Note: Materials may be edited for content and length.


Cite This Page:

American Academy of Neurology. "Epidural Steroid Injections Limited In Treating Back Pain, New Guideline Finds." ScienceDaily. ScienceDaily, 6 March 2007. <www.sciencedaily.com/releases/2007/03/070305203019.htm>.
American Academy of Neurology. (2007, March 6). Epidural Steroid Injections Limited In Treating Back Pain, New Guideline Finds. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2007/03/070305203019.htm
American Academy of Neurology. "Epidural Steroid Injections Limited In Treating Back Pain, New Guideline Finds." ScienceDaily. www.sciencedaily.com/releases/2007/03/070305203019.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) — Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) — Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins